However, in cancer, MET is frequently overexpressed and contributes to tumor progression by activating downstream oncogenic signaling pathways.[18] To assess MET activation in PDAC, we analyzed two publicly available transcriptomic datasets and observed significantly higher MET pathway activity in PDAC samples compared to normal pancreatic tissues (p < 0.001, Figure S2A, Supporting Information). This evidence concerns the gene MET and cancer.